Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Peri-operative Intervention With Nebulized Ipratropium Bromide in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial.
Verified date | September 2015 |
Source | Boehringer Ingelheim |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: China Food and Drug Administration (CFDA) |
Study type | Interventional |
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese peri-operative patients with COPD under general anaesthesia.
Status | Completed |
Enrollment | 192 |
Est. completion date | August 2015 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years to 75 Years |
Eligibility |
Inclusion criteria: - All patients must sign an informed consent. - Male or female patients aged >= 40 years and <= 80 years - All patients must be diagnosed with COPD and must meet the following spirometric criterion: post-bronchodilator forced expiratory volume in 1 second (FEV1) < 70% of forced vital capacity (FVC) at Screening Visit (Visit 1). - All patients have relatively stable COPD (i.e. have no COPD exacerbation within 4 weeks prior to Screening Visit). - All patients are about to receive selective surgical procedures of lobectomy or right bilobectomy or segmentectomy under general anaesthesia, whilst the estimated time of surgical procedures lasts for not less than 2 hours, and the estimated time of general anaesthesia lasts for not less than 3 hours and not longer than 5 hours. - Patients must be able to perform all study related procedures including technically acceptable pulmonary function tests (PFTs). Exclusion criteria: - Patients who need maintenance treatment of bronchodilators (including anticholinergics, ß-agonists, xanthines). - Patients with a recent history (i.e. six months or less) of myocardial infarction - Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year - Patients with symptomatic chronic heart failure (i.e. New York Heart Association functional class III-IV) - Known narrow angle glaucoma - Patients with prostatic hyperplasia or bladder neck obstruction with significant symptoms - Patients with a history of asthma, allergic rhinitis or who have a blood eosinophil count >= 600 / mm3 (0.6×10^9/L). A repeat eosinophil count will not be conducted in these patients |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | 244.2514.86008 Boehringer Ingelheim Investigational Site | Chengdu | |
China | 244.2514.86006 Boehringer Ingelheim Investigational Site | Guangzhou | |
China | 244.2514.86007 Boehringer Ingelheim Investigational Site | Guangzhou | |
China | 244.2514.86010 Boehringer Ingelheim Investigational Site | Guangzhou | |
China | 244.2514.86009 Boehringer Ingelheim Investigational Site | Hangzhou | |
China | 244.2514.86004 Boehringer Ingelheim Investigational Site | Shanghai | |
China | 244.2514.86002 Boehringer Ingelheim Investigational Site | Tianjin | |
China | 244.2514.86011 Boehringer Ingelheim Investigational Site | Wuhan | |
China | 244.2514.86012 Boehringer Ingelheim Investigational Site | Wuhan |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of FEV1 from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3) | treatment day 3 | No | |
Secondary | Change of FVC from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3) | treatment day 3 | No | |
Secondary | Main post-operative pulmonary complications (including pneumonia, atelectasis and acute respiratory failure) within three weeks after the surgery | 25 days | No | |
Secondary | Change of blood gas analyses from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3): arterial oxygen tension (PaO2) value, arterial oxygen saturation and arterial carbon dioxide tension (paCO2) value | treatment day 3 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|